Zr--Succinyldesferal-human anti-insulin-like growth factor 1 receptor monoclonal antibody R1507

Insulin-like growth factor 1 (IGF-1, 70 amino acids) is secreted by the liver and target tissues in response to growth hormone stimulation (1). IGF-1 plays an important role in cell growth and development. IGF-1 binds to IGF-1 receptor (IGF-1R) with ~1,000-fold higher affinity than to insulin receptor. IGF-1R is a transmembrane tyrosine kinase receptor and is also highly expressed in many human cancers (2). IGF-1R plays an important role in tumor proliferation, apoptosis, angiogenesis, and metastasis (3, 4). Triple negative breast tumors are negative for estrogen receptors, progesterone receptors, and . Patients with triple negative breast tumors have a lower survival rate than patients with estrogen receptor- or -positive breast tumors (5). IGF-1R is overexpressed in 36% of all triple negative breast carcinomas (6). Therefore, monitoring of IGF-1R expression in breast tumor lesions with a non-invasive imaging modality is important for development of therapeutic treatments of these patients with anti-IGF-1R monoclonal antibodies (7). The human anti-IGF-1R monoclonal antibody R1507 is directed against the extracellular domain of human IGF-1R (8). In this chapter, Heskamp et al. (9) radiolabeled the human anti-IGF-1R monoclonal antibody R1507 with Zr for imaging of IFG-1R expression with positron emission tomography (PET). Zr--Succinyldesferal-human anti-IGF-1R monoclonal antibody R1507 (Zr-R1507) has been evaluated in a triple negative breast cancer model in mice.